IPSC CENTURY THERAPEUTICS INC

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY.

A live webcast of the presentation will be available on the Investors page of Century’s website at . An archived replay will be available for at least 30 days.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases and cancer. The company’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit and connect with us on LinkedIn.

For More Information:

Century Therapeutics

Douglas Carr

Senior Vice President, Finance

JPA Health

Sarah McCabe



EN
14/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTURY THERAPEUTICS INC

 PRESS RELEASE

Century Therapeutics Reports Third Quarter 2025 Financial Results and ...

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026CNTY-308 advancing through IND-enabling studies to support planned clinical study initiation in 2026Estimated cash runway into 4Q 2027 PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)...

 PRESS RELEASE

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabe...

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate rapid reversal of diabetes and sustained normoglycemia, human C‑peptide production and mature GSIS, supported by scalable bioreactor-based manufacturingInvestigational New Drug (IND)-enabling studies on track to initiate by year-end 2025; IND submission planned as early as 2026 PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE)...

 PRESS RELEASE

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medici...

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY. A live webcast of the presentation will be available on ...

 PRESS RELEASE

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global ...

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. In addition, members of management will be available for me...

 PRESS RELEASE

Century Therapeutics Reports Second Quarter 2025 Financial Results and...

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functionally comparable to primary T cells, now in IND-enabling studies as a potential treatment for B-cell-mediated diseases; program expected to progress into the clinic in 2026 Dr. Brent Pfeiffenberger, CEO, appointed to Board ChairCash runway extended into fourth quarter 2027 PHILADELPHIA, Aug. 14, 2025 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch